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Abstract Ligands for the leukocyte adhesion molecule L-
selectin are expressed not only in lymph node high endothelial
venules (HEV) but also in the renal distal tubuli. Here we report
that L-selectin-reactive molecules in the kidney are chondroitin
sulfate and heparan sulfate proteoglycans of 500^1000 kDa,
unlike those in HEV bearing sialyl Lewis X-like carbohydrates.
Binding of L-selectin to these molecules was mediated by the
lectin domain of L-selectin and required divalent cations. Binding
was inhibited by chondroitinase and/or heparitinase but not
sialidase. Thus, L-selectin can recognize chondroitin sulfate and
heparan sulfate glycosaminoglycans structurally distinct from
sialyl Lewis X-like carbohydrates.
z 1999 Federation of European Biochemical Societies.
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1. Introduction
L-selectin, a leukocyte adhesion molecule, plays an impor-
tant role in lymphocyte homing and leukocyte in¢ltration to
the sites of in£ammation [1,2]. L-selectin consists of an NH2-
terminal C-type lectin domain, an EGF-like domain, short
consensus repeats, a transmembrane domain, and a short cy-
toplasmic tail [3,4]. By virtue of its C-type lectin domain,
L-selectin can recognize speci¢c carbohydrate-bearing ligands
on high endothelial venules (HEV) in lymph nodes such as
GlyCAM-1, CD34, podocalyxin-like protein, Sgp 200 and
MAdCAM-1 [5^10]. Recently, a major capping group of the
L-selectin ligands on HEV was reported to have a sialyl Lewis
X-like structure, 6-sulfo sialyl Lewis X [11]. Sialyl Lewis
X-like carbohydrates are also expressed in endothelial cells
in in£ammatory sites and may serve as L-selectin ligands in
the complement-dependent acute dermatitis, renal and cardiac
transplantation-associated acute rejection models in the rat
[12^14]. L-selectin ligands containing complex sulfated carbo-
hydrates, but not sialic acid or fucose residues, have also been
described. For example, heparan sulfate proteoglycan, sulfa-
tide and HNK-1 reactive sulfoglucuronyl glycolipids [15^17]
have been reported, although their biological signi¢cance re-
mains to be clari¢ed.
We reported previously that L-selectin ligands are expressed
not only in lymph node HEV but also in extravascular tissues,
such as the brain white matter, choroid plexus and renal tu-
buli [18]. The presence of L-selectin ligands in the kidney
apparently leads to pathological consequences in the rat ure-
teral obstruction model. Speci¢cally, upon obstruction of the
ureter, L-selectin binding molecules originally localized in tub-
ular epithelial cells are released within several hours into the
surrounding parenchymal tissue where abundant mononuclear
leukocytes subsequently in¢ltrate in an L-selectin-dependent
manner [19]. We have recently identi¢ed versican, a large
chondroitin sulfate proteoglycan, as one of the L-selectin
binding molecules in the kidney [20], although whether versi-
can is the sole L-selectin binding molecule in the kidney re-
mains to be determined.
In the present study, we performed histochemical as well as
biochemical characterization of L-selectin binding molecules
in the rat kidney. Our ¢ndings showed that L-selectin binding
molecules consist of two types of proteoglycans, namely chon-
droitin sulfate and heparan sulfate proteoglycans of 500^
1000 kDa, unlike those in the lymph node HEV.
2. Materials and methods
2.1. Animals and tissues
Eight-week-old male Wistar rats (Shionogi Pharmaceutical Co.,
Aburabi Laboratory, Osaka, Japan) were used throughout the study.
The experimental protocol was approved by the Ethics Review Com-
mittee for Animal Experimentation of Osaka University Medical
School. After exsanguination, the kidneys were removed, embedded
in Tissue-Tek O.C.T. compound (Sakura Fine Technical Co., Tokyo,
Japan), and stored at 380‡C until use.
2.2. Antibodies and enzymes
L-selectin-IgG chimera (LEC-IgG) is a recombinant soluble form of
rat L-selectin, produced in our laboratory as described previously [18].
Human poliovirus receptor (PVR)-IgG was a gift from Dr. J. Aoki
(Faculty of Pharmaceutical Sciences, University of Tokyo, Tokyo,
Japan). mAb (monoclonal antibody) KM93 [21] (anti-sialyl Lewis
X; mouse IgM), heparitinase (Flavobacterium heparinum), chondroiti-
nase ABC (Proteus vulgaris), and rat chondrosarcoma proteoglycan
were purchased from Seikagaku Kogyo Co. (Tokyo). mAb FH6 [22]
(anti-sialyl Lewis X-i; mouse IgM) was from Otsuka Pharmaceutical
Co. (Tokushima, Japan). mAbs G152 [11] (anti-6-sulfo sialyl Lewis X;
mouse IgM), HECA-452 [23] (anti-sialyl Lewis X-like carbohydrates;
rat IgM), and GS5 [19] (anti-sulfatide; mouse IgM) were gifts from
Dr. R. Kannagi (Aichi Cancer Center Research Institute, Nagoya,
Japan), Dr. E.C. Butcher (Stanford University), and Dr. Y. Suzuki
(School of Pharmaceutical Sciences, University of Shizuoka), respec-
tively. Hamster anti-rat L-selectin mAbs HRL3 and HRL4 were pre-
pared in our laboratory as described previously [24]. A rabbit anti-
human Tamm-Horsfall protein (THP) polyclonal antibody was pur-
chased from Biomedical Technologies Inc. (Stoughton, MA). Clostri-
dium perfringens neuraminidase and proteinase K-agarose were pur-
chased from Sigma Chemical Co. (St. Louis, MO). Arthrobacter
ureafaciens neuraminidase was purchased from Boehringer Mannheim
(Mannheim, Germany). Sialyl Lewis X-BSA was purchased from Ox-
ford GlycoSystems, Inc. (Abingdon, UK). All other reagents were of
analytical grade.
2.3. Immunohistochemistry
For immuno£uorescence staining, a mixture of LEC-IgG (8 Wg/ml)
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and anti-THP polyclonal antibody (1:400) was added to a ¢xed sec-
tion and incubated overnight at 4‡C. A mixture of FITC-labeled goat
anti-human IgG (1:500; absorbed with rabbit IgG) and TRITC-la-
beled goat anti-rabbit IgG (1:500; absorbed with human IgG) was
then placed on the section for 1 h. Immunoperoxidase staining was
performed as described previously [18].
2.4. Enzyme treatment
Acetone-¢xed sections or biotinylated high molecular size fractions
(fractions 12^14) described below were treated with neuraminidase
(100 mU/ml in PBS [phosphate-bu¡ered saline], pH 7.4), heparitinase
or chondroitinase (50^500 mU/ml in 20 mM Tris-HCl, 0.05% Tween
20, 1 mM PMSF, 5 Wg/ml pepstatin, 4 Wg/ml leupeptin, 3.3 mM
CaCl2) for 3 h at 37‡C. Protease activity in these reaction mixtures
was negligible, which was con¢rmed by comparing the intensity of
anti-THP antibody staining in immunohistology before and after
treating the frozen section with these reaction mixtures.
2.5. Gel permeation column chromatography
Renal tubuli were collected from the rat kidneys according to the
method of Krisko et al. [25]. The collected fraction was lysed with
solubilizing bu¡er containing 4 M guanidine-HCl, 50 mM Tris-HCl
(pH 8.0), 1% NP-40, 10 mM EDTA, 10 mM N-ethylmaleimide and
1 mM PMSF. The tubular lysates (460 Wl) were applied to a Sephacryl
S-300 column (1U20 cm) equilibrated with PBS containing 0.05%
Tween 20, and 50 fractions (460 Wl/tube) were collected.
2.6. Dot blot analysis
The above-mentioned fractions were blotted onto a Hybond-C ni-
trocellulose membrane. After blocking, the blot was incubated with
LEC-IgG (0.5 Wg/ml) for 1 h. After washing, the blot was incubated
with HRP (horseradish peroxidase)-conjugated goat anti-human IgG
(1:2000). After washing again, LEC-IgG binding was detected with
ECL Western blotting detection reagents (Amersham, Buckingham-
shire, UK).
2.7. Immunoprecipitation
The high molecular size fractions (fractions 12^14) labeled with 100
Wg/ml of NHS-LC-biotin (Pierce Chemical Co., Rockford, IL, USA)
were ¢rst treated with or without glycosaminoglycan-degrading en-
zymes, and then incubated with protein A beads coupled with 3.5 Wg
of LEC-IgG or human poliovirus receptor (PVR)-IgG. Immunopre-
cipitates were subjected to SDS-agarose-PAGE on a gel containing
1.75% polyacrylamide and 0.5% agarose [20]. After electrophoresis,
the samples were transferred onto an IPVH membrane (Millipore
Co., Bedford, MA, USA), followed by detection using an ABC-kit
(Vector Laboratories, Burlingame, CA, USA) and ECL Western blot-
ting detection reagents.
3. Results and discussion
3.1. L-selectin binding molecules are localized in renal distal
tubuli
To examine the distribution of L-selectin binding molecules
in the kidney, renal frozen sections were stained by two-color
immuno£uorescence using LEC-IgG and a polyclonal anti-
body against THP, known to be selectively expressed in renal
distal tubuli [26] (Fig. 1a,b). The stainings overlapped each
other in renal tubuli of the outer medulla (Fig. 1c, yellow),
although anti-THP staining was also observed in the cortex
where LEC-IgG staining was not observed (data not shown).
These results extend our previous ¢ndings [18] by showing
that L-selectin ligands are selectively expressed in the distal
tubuli of the outer medulla of the kidney.
3.2. L-selectin binding molecules in the kidney are neither sialyl
Lewis X-like carbohydrates nor sulfatide
Glycoprotein ligands for L-selectin are known to be modi-
¢ed with sialyl Lewis X-like carbohydrates, which represent
the essential epitope for L-selectin binding [11,12,27,28]. To
examine whether L-selectin binding molecules in the kidney
also bear sialyl Lewis X-like structures, we next compared
their distribution immunohistologically. Whereas L-selectin
binding molecules showed restricted expression in the distal
tubuli of the outer medulla (Fig. 2a) as described above, sialyl
Lewis X-like structures showed di¡erent distribution patterns.
For instance, sialyl Lewis X antigen recognized by KM93 [21]
was restricted to the intermediate tubuli in the inner and outer
medulla (Fig. 2e). Sialyl Lewis X-i antigen recognized by FH6
[22] was detected in the proximal tubuli in the cortex (Fig. 2f).
In addition, treatment of the renal frozen section with neur-
aminidase did not a¡ect the binding of LEC-IgG to the kidney
(Fig. 2c), while this treatment completely blocked the binding
of LEC-IgG to the mesenteric lymph node HEV of the rat
(data not shown). These results suggest that sialyl Lewis
X-like carbohydrates expressed in the kidney are not reactive
with L-selectin, in contrast to those expressed in lymph node
HEV. One of the possible reasons for this di¡erence is that
additional modi¢cation of sialyl Lewis X antigen, such as
sulfation, is required for the high a⁄nity recognition by
L-selectin, hence the interaction of L-selectin with a simple
sialyl Lewis X antigen may be too weak, as demonstrated
by others [11,28]. The absence of 6-sulfo sialyl Lewis X rec-
ognized by G152 [11] (Fig. 2g) and various variant-type sialyl
Lewis X structures containing 6-sulfo sialyl Lewis X recog-
nized by HECA452 [23] (Fig. 2h) in the kidney is compatible
with this notion.
Sulfatide, one of the sulfated glycolipids, is reactive with
L-selectin and expressed in the kidney [29]. Consistently, the
staining pattern with the anti-sulfatide mAb GS5 (Fig. 2d)
was similar to that with LEC-IgG (Fig. 2a). However, in clear
contrast to the previous observations that L-selectin binding
to sulfatide is only partially dependent on divalent cations
[16], LEC-IgG binding to the distal tubuli was completely
abolished by EDTA treatment (Fig. 2b), suggesting that
sulfatide expressed in the tubuli does not serve as the L-selec-
tin binding molecule. This may be due to the physical inacces-
sibility of L-selectin to sulfatide on frozen sections, since sul-
fatide has only a short sulfated sugar chain. On the other
hand, proteoglycans containing clustered long sulfated sugar
chains described below may be more readily accessible to
L-selectin.
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Fig. 1. Immuno£uorescence analysis of the rat kidney. Green £uo-
rescence (a, LEC-IgG staining) and red £uorescence (b, anti-THP
staining) were detected separately using a £uorescence microscope
BX-FLA (Olympus). In c, both images were superexposed on a sin-
gle ¢lm. Magni¢cation: U125.
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Fig. 2. Immunohistochemical staining of the rat kidney. Renal frozen sections were stained with LEC-IgG (a, b and c), GS5 (d), KM93 (e),
FH6 (f), G152 (g), or HECA-452 (h) in the presence (b) or absence (a and c^h) of 10 mM EDTA. In c, the section was treated with neurami-
nidase (from Clostridium perfringens). Magni¢cation: U25.
Fig. 3. LEC-IgG binding to the distal tubuli of the renal medulla after treatment with glycosaminoglycan degrading enzymes. Before incubation
with LEC-IgG, the sections were treated with bu¡er alone (a), 50 mU/ml of chondroitinase (b), or heparitinase (c). Magni¢cation: U75.
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3.3. L-selectin binding to renal tubuli is dependent on
chondroitin sulfate and heparan sulfate chains
We have recently reported that versican, a large chondroitin
sulfate proteoglycan, from a renal adenocarcinoma cell line, is
reactive with L-selectin and that at least a subset of versican
species present in the renal tubuli is reactive with L-selectin
[20]. Thus, we next examined the e¡ect of chondroitinase as
well as other glycosaminoglycan-degrading enzymes on the
binding of LEC-IgG to the distal tubuli. Not only chondroi-
tinase ABC (Fig. 3b) but also heparitinase treatment (Fig. 3c)
strongly reduced the LEC-IgG binding, whereas bu¡er treat-
ment did not (Fig. 3a). The e¡ects of these enzymes were
apparently speci¢c, since heparitinase activity was undetect-
able in the reaction mixture of chondroitinase ABC, and vice
versa, chondroitinase activity was undetectable in the reaction
mixture of heparitinase under the condition employed (data
not shown). Treatment with keratanase did not a¡ect the
staining intensity with LEC-IgG (data not shown). These re-
sults suggest that chondroitin sulfate and heparan sulfate
chains are required for L-selectin binding to renal tubuli
and that versican is not the sole L-selectin binding molecule
in the kidney [20].
3.4. L-selectin reactive molecules in the kidney are high
molecular size chondroitin sulfate and heparan sulfate
proteoglycans
In the next step, we subjected tubular lysates to Sephacryl
S-300 gel permeation column chromatography for further
characterization of L-selectin binding components in the kid-
ney. First, fractions were dot blotted and examined for their
ability to bind L-selectin by incubating the blot with LEC-IgG
and HRP-labeled goat anti-human IgG. Densitometric exami-
nation of each spot showed that most of the L-selectin bind-
ing components were eluted in the high molecular size (s 400
kDa) fractions (Fig. 4A). Next, we biotinylated the L-selectin
reactive high molecular size fractions (fractions 12^14) and
performed immunoprecipitation analyses. As shown in Fig.
4B, the high molecular size components (approximately 500^
1000 kDa) were reactive with LEC-IgG but not with control
Ig-chimera (lanes 1 and 2). The binding was strongly inhibited
by treatment of the high molecular size components with
chondroitinase ABC and/or heparitinase (lanes 3^5), consis-
tent with the above notion that L-selectin binding to the renal
tubuli is dependent on chondroitin sulfate and heparan sulfate
glycosaminoglycans. In addition, proteinase K treatment also
abolished the binding (lane 6), indicating that L-selectin bind-
ing components have a protein backbone. In contrast, siali-
dases (lanes 7 and 8) did not inhibit the binding, in agreement
with the above results of immunohistochemical analysis. The
binding was abolished with EDTA (lane 9) or blocking mAb
HRL3 (lane 11), reactive against the lectin domain of L-selec-
tin, but not with the non-blocking mAb HRL4 (lane 10).
These results indicate that L-selectin reactive components in
the kidney are chondroitin sulfate and/or heparan sulfate pro-
teoglycans of approximately 500^1000 kDa and that their
glycosaminoglycan moieties are recognized by the lectin do-
main of L-selectin. However, it should be noted that hepar-
itinase treatment alone of the high molecular size components
appeared to abolish L-selectin binding in our immunoprecipi-
tation analysis (Fig. 4B, lane 4). This cannot simply be ex-
plained by a sensitivity problem of the detection system used,
since a longer exposure (s 1 h) also failed to change the
results (data not shown). It is possible that the presence of
both chondroitin sulfate and heparan sulfate proteoglycans
might have synergistically enhanced their reactivity with
L-selectin, due possibly to molecular interactions between
these proteoglycans and/or due to the presence of both types
of the glycosaminoglycan chains on a single core protein
backbone.
We are uncertain at present why L-selectin can interact with
structurally distinct glycans, such as sialyl Lewis X-like oligo-
saccharides and highly sulfated glycosaminoglycans. It could
be that sulfation on the glycans and/or the clustered nature of
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Fig. 4. Sephacryl S-300 gel permeation column chromatography and
immunoprecipitation analysis. A: Fractionation of tubular lysates
with Sephacryl S-300 gel permeation column chromatography.
Closed circles, absorbance at 280 nm. Open circles, relative densito-
metric intensity of each fraction probed with LEC-IgG in reference
to the densitometric intensity of 1 mg/ml of sialyl Lewis X-BSA
probed with LEC-IgG. Molecular standards used were: blue dextran
(2000 kDa), thyroglobulin (669 kDa), ferritin (440 kDa) and aldo-
lase (158 kDa). Vo, void volume. Vt, column volume. B: Biotiny-
lated high molecular size fractions (fractions 12^14) were either un-
treated (lanes 1, 2, and 9^11) or treated with 0.5 U/ml
chondroitinase ABC (lane 3), 0.5 U/ml heparitinase (lane 4), a mix-
ture of chondroitinase ABC and heparitinase (lane 5), 20 mU/ml
proteinase K-agarose (lane 6), 0.1 U/ml neuraminidase (from Clos-
tridium perfringens ; lane 7), or 0.1 U/ml neuraminidase (from Ar-
throbacter ureafaciens ; lane 8) at 37‡C for 3 h, and then incubated
with protein G beads coated with a control Ig chimera, PVR-IgG,
(lane 1) or LEC-IgG (lanes 2^11), in the absence (lanes 1^8) or
presence of 10 mM EDTA (lane 9), 20 Wg/ml HRL4 (lane 10), or
20 Wg/ml HRL3 (lane 11). Molecular standards used were: rat chon-
drosarcoma proteoglycan (2500 kDa), thyroglobulin (669 kDa), and
ferritin (440 kDa).
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the negatively charged glycans are key elements for L-selectin
binding, although veri¢cation of this point awaits detailed
characterization of the sugar binding sites on L-selectin.
It has been reported that endothelial heparan sulfate pro-
teoglycans can present chemokines to leukocytes [30]. Since
L-selectin binding components described in this study are also
proteoglycans, it would be interesting to examine if they also
bind chemokines similar to endothelial heparan sulfate pro-
teoglycans. If so, they might function as presenting molecules
for chemokines providing a link between selectin-mediated
and integrin-mediated adhesion systems.
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